Immunocore’s ImmTAC ® Platform Gains Big Pharma Recognition with Genentech Pact
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 7 (Table of Contents)
Published: 19 Jul-2013
DOI: 10.3833/pdr.v2013.i7.1967 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Medigene spin-off Immunocore has formed its first major collaboration by partnering with Roche’s Genentech for the discovery and development of multiple novel cancer targets using its ImmTAC® (immune mobilising mTCR against cancer) technology platform...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS